Immupharma Hosts Lupuzor ™ Symposium with Lupuzor’s™ Inventor, Prof. Sylviane Muller

8th June 2016 - 2:03 pm

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to confirm that today and tomorrow, 8 & 9 June, it is hosting a number of presentations on Lupuzor™, the Company’s lead compound for the potential treatment of Lupus, a chronic auto-immune disease, currently in a pivotal Phase III trial.

This event, to be attended by investors, sell side analysts and media, is being hosted with Prof. Muller, inventor of Lupuzor™ presenting on the unique ‘Mechanism of Action’ of Lupuzor™, also known by its chemical name ‘Forigerimod’ or ‘P140’. Prof. Muller will also provide further evidence of the role the P140 molecule can take in the potential treatment of other autoimmune diseases.

Prof. Sylviane Muller was recently honoured by receiving ‘The CNRS Medal of Innovation’ for her discoveries made on the mechanism of action of Lupuzor™ and its applications to other autoimmune diseases.

A video of the presentation will be available to view on the Company’s website from Monday 13 June on:

No material new information relating to ImmuPharma will be disclosed during this event.

Share this article